

Pharmaceuticals at a Glance

CEO	Joe Jimenez
Headquarters	Basel, Switzerland
Major R&D sites	Basel, Switzerland Cambridge, Massachusetts, USA Changshu, China East Hanover, New Jersey, USA Horsham, England Shanghai, China
Major production sites	Barbera, Spain Basel, Switzerland Chang Ping, China Changshu, China Grimsby, England Horsham, England Huningue, France Kurtkoy, Turkey Ringaskiddy, Ireland Schweizerhalle, Switzerland Sasayama, Japan Singapore Stein, Switzerland Suffern, New York, USA Torre, Italy Wehr, Germany
Website address	www.novartis.com
2009 net sales	USD 28.5 billion
2009 full-time associates	56 310
Leading products	<i>Diovan/Co-Diovan</i> – Hypertension <i>Gleevec/Glivec</i> – Cancer <i>Zometa</i> – Cancer <i>Femara</i> – Breast cancer <i>Sandostatin</i> – Acromegaly <i>Lucentis</i> – “Wet” age-related macular degeneration <i>Exelon/Exelon Patch</i> – Alzheimer’s disease <i>Exforge</i> – Hypertension <i>Exjade</i> – Iron chelation <i>Reclast/Aclasta</i> – Osteoporosis <i>Xolair</i> – Asthma <i>Tekturna/Rasilez</i> – Hypertension <i>Tasigna</i> – Cancer <i>Galvus/Eucreas</i> – Diabetes <i>Certican</i> – Transplantation

All product names appearing in italics are trademarks licensed to or owned by Novartis Group companies.